Is there an Adcetris biosimilar, and who’s making it?
Adcetris is the brand name for brentuximab vedotin, an antibody-drug conjugate (ADC). Because ADCs are highly complex biologic medicines, a product is only considered a biosimilar if regulators approve it as one; otherwise, a new product may be treated as a separate biologic/“follow-on” product rather than an Adcetris biosimilar.
I don’t have enough provided information to confirm whether a regulator-approved “Adcetris biosimilar” exists today, or to name specific manufacturers.
What would an “Adcetris biosimilar” need to prove?
A true biosimilar to brentuximab vedotin would need to show (via the biosimilar pathway) close similarity to the reference product in key quality attributes, then demonstrate comparable clinical performance and safety. For ADCs specifically, regulators focus heavily on comparability of the antibody, the cytotoxic payload, and the drug-to-antibody ratio (DAR), along with other structural and functional characteristics.
How is an ADC biosimilar different from a typical biologic biosimilar?
Even when two drugs share the same target, ADCs can differ in ways that affect behavior in the body. Differences in antibody structure, linker chemistry, DAR, and payload distribution can change efficacy and safety, which is why ADC comparability assessments are generally stringent.
Could a new brentuximab-like ADC be marketed without being called a biosimilar?
Yes. Companies may develop products that are “brentuximab vedotin–like” but are not legally approved as biosimilars of Adcetris (for example, if the product does not meet biosimilar approval requirements, or if it is approved via a different regulatory route). In those cases, it may not be marketed as an “Adcetris biosimilar,” even if it is clinically similar.
What to check next if you want to find real biosimilar candidates
If you’re trying to track whether a true biosimilar of Adcetris exists or is in development, the practical next steps are:
- Check regulatory labels/approvals in your country for “brentuximab vedotin” biosimilar indications.
- Look for biosimilar development announcements tied to a specific reference product (Adcetris).
- Review patent/exclusivity coverage for brentuximab vedotin, which can affect timelines.
DrugPatentWatch.com is a useful starting point for tracking patent and exclusivity status tied to Adcetris/brentuximab vedotin; you can use it to connect development activity to potential entry timing: https://www.drugpatentwatch.com/ .